Literature DB >> 25403664

Inappropriate continued empirical vancomycin use in a hospital with a high prevalence of methicillin-resistant Staphylococcus aureus.

Nak-Hyun Kim1, Hei Lim Koo2, Pyoeng Gyun Choe, Pyeong Gyun Choe3, Shinhye Cheon1, Moonsuk Kim, Moon Suk Kim1, Myung Jin Lee1, Younghee Jung, Young Hee Jung1, Wan Beom Park1, Kyoung-Ho Song1, Eu Suk Kim1, Ji Hwan Bang1, Hong Bin Kim1, Sang Won Park1, Nam Joong Kim4, Myoung-don Oh1, Eui Chong Kim5.   

Abstract

Vancomycin is frequently inappropriately prescribed, especially as empirical treatment. The aim of this study was to evaluate (i) the amount of inappropriate continued empirical vancomycin use as a proportion of total vancomycin use and (ii) the risk factors associated with inappropriate continued empirical vancomycin use. We reviewed the medical records of adult patients who had been prescribed at least one dose of parenterally administered vancomycin between January and June 2012, in a single tertiary care hospital. When empirically prescribed vancomycin treatment was continued after 96 h without documentation of beta-lactam-resistant Gram-positive microorganisms in clinical specimens with significance, the continuation was considered inappropriate, and the amount used thereafter was considered inappropriately used. We identified risk factors associated with inappropriate continued empirical vancomycin use by multiple logistic regression. During the study period, the amount of parenterally administered vancomycin prescribed was 34.2 defined daily doses (DDDs)/1,000 patient-days (1,084 prescriptions for 971 patients). The amount of inappropriate continued empirical vancomycin use was 8.5 DDDs/1,000 patient-days, which represented 24.9% of the total parenterally administered vancomycin used (8.5/34.2 DDDs/1,000 patient-days). By multivariate analyses, inappropriate continued empirical vancomycin use was independently associated with the absence of any documented etiological organism (adjusted odds ratio [aOR], 1.60 [95% confidence interval {CI}, 1.06 to 2.41]) and suspected central nervous system (CNS) infections (aHR, 2.33 [95% CI, 1.20 to 4.50]). Higher Charlson's comorbidity index scores were inversely associated with inappropriate continued empirical vancomycin use (aHR, 0.90 [95% CI, 0.85 to 0.97]). Inappropriate continued empirical vancomycin use represented 24.9% of the total amount of vancomycin prescribed, which indicates room for improvement.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25403664      PMCID: PMC4335878          DOI: 10.1128/AAC.04523-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship.

Authors:  Timothy H Dellit; Robert C Owens; John E McGowan; Dale N Gerding; Robert A Weinstein; John P Burke; W Charles Huskins; David L Paterson; Neil O Fishman; Christopher F Carpenter; P J Brennan; Marianne Billeter; Thomas M Hooton
Journal:  Clin Infect Dis       Date:  2006-12-13       Impact factor: 9.079

2.  General practice fundholding: observations on prescribing patterns and costs using the defined daily dose method.

Authors:  M Maxwell; D Heaney; J G Howie; S Noble
Journal:  BMJ       Date:  1993-11-06

3.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

Review 4.  Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat.

Authors:  Hajo Grundmann; Marta Aires-de-Sousa; John Boyce; Edine Tiemersma
Journal:  Lancet       Date:  2006-09-02       Impact factor: 79.321

5.  Evaluation of vancomycin use in a pediatric teaching hospital based on CDC criteria.

Authors:  B A Logsdon; K R Lee; G Luedtke; F F Barrett
Journal:  Infect Control Hosp Epidemiol       Date:  1997-11       Impact factor: 3.254

6.  A trial of discontinuation of empiric vancomycin therapy in patients with suspected methicillin-resistant Staphylococcus aureus health care-associated pneumonia.

Authors:  John M Boyce; Olivia-Fabiola Pop; Odaliz Abreu-Lanfranco; Whitney Y Hung; Ann Fisher; Afshin Karjoo; Benjamin Thompson; Zenon Protopapas
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

Review 7.  Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC).

Authors: 
Journal:  Am J Infect Control       Date:  1995-04       Impact factor: 2.918

8.  Case-control study to identify factors associated with mortality among patients with methicillin-resistant Staphylococcus aureus bacteraemia.

Authors:  D Marchaim; K S Kaye; V G Fowler; D J Anderson; V Chawla; Y Golan; A W Karchmer; Y Carmeli
Journal:  Clin Microbiol Infect       Date:  2009-09-11       Impact factor: 8.067

9.  Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India.

Authors:  Hare Krishna Tiwari; Malay Ranjan Sen
Journal:  BMC Infect Dis       Date:  2006-10-26       Impact factor: 3.090

10.  Analysis of vancomycin use and associated risk factors in a university teaching hospital: a prospective cohort study.

Authors:  Moacyr S Junior; Luci Correa; Alexandre R Marra; Luis F A Camargo; Carlos A P Pereira
Journal:  BMC Infect Dis       Date:  2007-08-01       Impact factor: 3.090

View more
  7 in total

1.  Perioperative antibiotic use in vagus nerve stimulator implantation: a clinical series.

Authors:  Jeffrey S Raskin; Daniel Hansen; Arvind Mohan; I-Wen Pan; Daniel J Curry; Sandi Lam
Journal:  Childs Nerv Syst       Date:  2017-03-20       Impact factor: 1.475

2.  Comparison of Clinical Outcomes for Glycopeptides and Beta-Lactams in Methicillin-Susceptible Staphylococcus Aureus Bloodstream Infections.

Authors:  Yeon Ju La; Hye Rim Kim; Dong Hyun Oh; Jin Young Ahn; Yong Chan Kim
Journal:  Yonsei Med J       Date:  2022-07       Impact factor: 3.052

3.  Effect of an intervention targeting inappropriate continued empirical parenteral vancomycin use: a quasi-experimental study in a region of high MRSA prevalence.

Authors:  Pyoeng Gyun Choe; Hei Lim Koo; Doran Yoon; Ji Yun Bae; Eunyoung Lee; Joo-Hee Hwang; Kyoung-Ho Song; Wan Beom Park; Ji Hwan Bang; Eu Suk Kim; Hong Bin Kim; Sang Won Park; Myoung-Don Oh; Nam Joong Kim
Journal:  BMC Infect Dis       Date:  2018-04-16       Impact factor: 3.090

4.  Evaluation of vancomycin use in university-affiliated hospitals in Southern Khorasan Province (East Iran) based on HICPAC guidelines.

Authors:  Motahare Mahi-Birjand; Masood Ziaee; Bita Bijari; Reza Khalvati; Mohammad Reza Abedini; Hasan Golboei Mousavi; Arash Ziaee
Journal:  Drug Healthc Patient Saf       Date:  2019-04-08

5.  Evaluation of current practice of antimicrobial use and clinical outcome of patients with pneumonia at a tertiary care hospital in Ethiopia: A prospective observational study.

Authors:  Theodros Fenta; Ephrem Engidawork; Wondwossen Amogne; Alemseged Beyene Berha
Journal:  PLoS One       Date:  2020-01-30       Impact factor: 3.240

6.  Antimicrobial Activity and Phytochemical Analysis of Organic Extracts from Cleome spinosa Jaqc.

Authors:  Ana P Sant'Anna da Silva; Luís C Nascimento da Silva; Caíque S Martins da Fonseca; Janete M de Araújo; Maria T Dos Santos Correia; Marilene da Silva Cavalcanti; Vera L de Menezes Lima
Journal:  Front Microbiol       Date:  2016-06-28       Impact factor: 5.640

7.  Antimicrobial Time-Out for Vancomycin by Infectious Disease Physicians Versus Clinical Pharmacists: A Before-After Crossover Trial.

Authors:  Shinya Hasegawa; Yasuaki Tagashira; Shutaro Murakami; Yasunori Urayama; Akane Takamatsu; Yuki Nakajima; Hitoshi Honda
Journal:  Open Forum Infect Dis       Date:  2021-03-14       Impact factor: 3.835

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.